sur Solti
TOP-REAL Study Employs Digital Monitoring for Breast Cancer Treatment
Solti, an academic cancer research group, unveiled the innovative TOP-REAL study at the ESMO AI & Digital Oncology 2026 congress. The study aims to explore whether digital tools can help earlier detection of toxicities in HER2-positive metastatic breast cancer patients receiving first-line treatment with trastuzumab deruxtecan plus pertuzumab.
The study, in collaboration with Unicancer and WSG, focuses on implementing proactive monitoring through electronic patient-reported outcomes, pulse oximetry, and smartwatch data. This approach aims to anticipate and manage toxicities, thereby preserving the continuity of effective cancer treatments.
Approximately 300 patients across Spain, France, and Germany are expected to participate, including individuals underrepresented in earlier trials. These measures could improve quality of life and clinical outcomes for patients during treatment.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Solti